|Dr. Steven M. Fruchtman||CEO, Pres & Director||805.72k||N/A||1951|
|Dr. E. Premkumar Reddy||Founder, Lead Scientific Advisor & Director||30k||N/A||1944|
|Dr. Manoj Maniar||Sr. VP of Product Devel.||544.84k||N/A||1963|
|Dr. Ramesh Kumar||Advisor||732.68k||N/A||1956|
|Mr. Mark Patrick Guerin||Chief Financial Officer||N/A||N/A||1969|
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; a license and collaboration agreement with HanX Biopharmaceuticals, Inc.; and a collaboration agreement with Inceptua Medicines Access for a pre-approval access program related to intravenous rigosertib. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Onconova Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.